Read + Share
Tseng KY, Yang MY, Chen WS, Jiang JK, et al. Combining moderate dosage of Bevacizumab with TAS-102 provides longer
progression-free time in refractory metastatic colorectal Cancer. Int J Colorectal Dis 2024;39:195.
PMID: 39630293
|
 |
|
Tseng KY, Yang MY, Chen WS, Jiang JK, et al. Combining moderate dosage of Bevacizumab with TAS-102 provides longer
progression-free time in refractory metastatic colorectal Cancer. Int J Colorectal Dis 2024;39:195.
PMID: 39630293
|
|
|
|